Amelparib

Amelparib (JPI-289 free base) is a potent, orally active, and water-soluble inhibitor of PARP-1. Amelparib inhibits PARP-1 activity (IC50=18.5 nM) and cellular PAR formation (IC50=10.7 nM) in the nanomolar range. Amelparib is a potential neuroprotective agent. Amelparib has the potential for the research of acute ischaemic stroke[1].

Product Specifications

CAS Number

[1227156-72-0]

Product Name Alternative

JPI-289 (free base)

UNSPSC

12352005

Target

PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/amelparib.html

Purity

99.17

Solubility

DMSO : 100 mg/mL (ultrasonic; adjust pH to 2 with 1M HCl)

Smiles

O=C1C2=C(C3=C(C=C(C=C3N1)CN4CCOCC4)OCC)NCCC2

Molecular Formula

C19H25N3O3

Molecular Weight

343.42

References & Citations

[1]Kim Y, et al. Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. Clin Exp Pharmacol Physiol. 2017;44 (6) :671-679.|[2]Youngchul Kim, et al. Early treatment with poly (ADP-ribose) polymerase-1 inhibitor (JPI-289) reduces infarct volume and improves long-term behavior in an animal model of ischemic stroke. Molecular neurobiology 55 (2018) : 7153-7163.